lansoprazole / Generic mfg. - LARVOL DELTA

Repurposing of lansoprazole and nitazoxanide as NR2F2 inhibitors in the gastric cancer cell line GCIY: computational insights and siRNA-mediated in vitro tests. (PubMed, Front Chem) - "We identified lapatinib, glyburide, nitazoxanide, and lansoprazole as modulators of NR2F2-dependent reporter activity. Taken together, our data extend current evidence that NR2F2 is a ligandable orphan receptor whose transcriptional output can be pharmacologically tuned. Moreover, our findings provide new chemical tools for probing NR2F2 biology and nominate clinically used molecules as starting points for therapeutic or repurposing strategies targeting NR2F2-dependent programs."

Journal • Preclinical • Gastric Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Tragopogon coelesyriacus Boiss. attenuates ethanol-induced gastric ulcer in vivo: modulation of oxidative stress, inflammation, and apoptosis. (PubMed, PLoS One) - "Rats were aligned in 5 groups and pretreated with either normal saline, lansoprazole, or METC (200 and 400 mg/kg) before 5 mL/kg ethanol-induced gastric ulceration...Additionally, METC (200 and 400 mg/kg) remarkably modulated apoptotic proteins, lowering Bax by 31.10% and 45.50%, and increasing HSP 70 by 28.12 and 65.5%, respectively. The outcomes highlight the significant gastroprotective potential of Tragopogon coelesyriacus, which was mainly associated with its antioxidant, anti-inflammatory, and anti-apoptosis properties, making it a viable source for gastric ulcer management."

Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Inflammation • Peptic Ulcer • CAT • IL10 • IL6 • TNFA

Study to Evaluate the Safety, Efficacy of Tegoprazan for the Prevention of PUD in Patients on Treatment With NSAIDs (clinicaltrials.gov) - P3 | N=392 | Completed | Sponsor: HK inno.N Corporation | Recruiting ➔ Completed

Trial completion • Gastroenterology • Gastrointestinal Disorder • Peptic Ulcer

Neuroregulators for the Treatment of Diseases Associated With Esophageal-brain-gut Axis Communication Abnormalities. (clinicaltrials.gov) - P=N/A | N=610 | Recruiting | Sponsor: Hualien Tzu Chi General Hospital | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • CNS Disorders • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Immunology

QT Prolongation, Ventricular Arrhythmia, and Cardiac Arrest Signals During Ceftriaxone Co-therapy with Individual Proton Pump Inhibitors: A Multidatabase Study. (PubMed, Cardiovasc Toxicol) - "The analyses corroborated the initial findings (lansoprazole vs. other PPIs, multivariate HR = 1.30; 95% CI: 1.10-1.54), with the risk associated with the three PPI combinations ranked as lansoprazole > pantoprazole > omeprazole. Lansoprazole co-use confers a higher risk of QVC, whereas omeprazole appears relatively safer. Therefore, prospective confirmation is warranted."

Journal • Cardiovascular • Critical care

Effect of Vitamin D, Verapamil, and Lansoprazole on residual β-cell function in children with newly diagnosed type 1 diabetes: an open-label randomized controlled pilot trial (ESPE 2026) - No abstract available

Clinical • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Healing of Anastomotic Ulcer With Vonoprazan: A Case Report (ACG 2026) - "A pharmacodynamic study comparing vonoprazan 20 mg daily with lansoprazole 30 mg daily demonstrated more rapid, potent, and prolonged intragastric acid suppression with vonoprazan (2). Figure: Figure 2. Repeat EGD in 6 months following therapy with vonoprazan and sucralfate, showing complete healing of the previously seen esophagitis and marginal ulcer."

Case report • Clinical • Cardiovascular • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Peptic Ulcer • GAST

Differential fracture risk among proton pump inhibitors in older adults: evidence network and pharmacovigilance validation. (PubMed, Front Pharmacol) - "Compared with non-PPI users, omeprazole (OR 1.51, 95%CI 1.36-1.67), rabeprazole (OR 1.47, 95%CI 1.22-1.78), pantoprazole (OR 1.44, 95%CI 1.28-1.62), and lansoprazole (OR 1.32, 95%CI 1.14-1.53) were associated with a significantly increased risk of any-site fracture...Consistent with NMA findings, omeprazole exhibited a significant fracture risk signal (ROR 1.25, 95%CI 1.03-1.51), while esomeprazole showed no significant signal for overall fracture (ROR 0.89, 95%CI 0.66-1.20)...This discordance indicates that absence of a fracture signal should not imply skeletal safety. These findings provide evidence-based guidance for individualized PPI prescribing in elderly patients, with careful benefit-risk assessment for those requiring extended-duration PPI regimens."

Adverse events • Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • ROR1

Proton Pump Inhibitor-Associated Rhabdomyolysis: A Systematic Review of Pharmacovigilance Disproportionality Studies (ACG 2026) - "Pantoprazole was the weakest and nonsignificant in the Italian data (ROR 1.15; 95% CI 0.90-1.49). From 251 records, 196 were screened after duplicate removal. A disproportionate signal linking PPIs to rhabdomyolysis was identified across all three databases, with the magnitude varying by agent. In FAERS, all five PPIs showed significant RORs, with lansoprazole the strongest (ROR 12.67; 95% CI 11.66-13.77); esomeprazole, omeprazole, and rabeprazole were consistently significant across FAERS and JADER."

Adverse events • Review • Musculoskeletal Pain • ROR1

Proton Pump Inhibitors and H2-Receptor Blockers as Culprit Agents in Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis: A Systematic Review of Case Reports (ACG 2026) - "While antibiotics, anticonvulsants, and allopurinol are well-established culprits, proton pump inhibitors (PPIs) and H2-receptor blockers (H2RBs), among the most widely prescribed drug classes globally, are underrecognized triggers...PPIs were implicated in 62% of cases; lansoprazole, omeprazole, and pantoprazole were most frequent. H2RBs accounted for 38%, with ranitidine and cimetidine most common... Twenty studies met inclusion criteria, including one two-patient case series, yielding 21 cases (10 TEN, 11 SJS). Median age was 50 years; 62% were female. Median latency to onset was 10 days."

Case report • Clinical • Review • Acute Respiratory Distress Syndrome • Cardiovascular • Infectious Disease • Renal Disease • Respiratory Diseases • Septic Shock • Steven-Johnson Syndrome

Tegoprazan Provides Superior Healing and Maintenance of Conclusive Gastroesophageal Reflux Disease Per Lyon Consensus Endoscopic Criteria Than Lansoprazole: Post-Hoc Analysis of the TRIUMpH Randomized Controlled Trial (ACG 2026) - P3 | "There were no differences in age, gender, race/ethnicity and LA EE grades between patients randomized to tegoprazan (n=623, mean age 53 yrs, 53% female, 67% conclusive GERD) and lansoprazole (n=622, mean age 54 yrs, 52% female, 64% conclusive GERD). In the modified intention-to-treat (m-ITT) population, rates of healed EE were higher with tegoprazan compared to lansoprazole among patients with conclusive GERD per Lyon 2.0 (LA grades B-D) at week 2 (75.4% vs 60.7%, p< 0.0001) and cumulatively by week 8 (83.4% vs 72.7%, p=0.0005), while no difference was observed between groups at both time points for inconclusive GERD (LA grade A). Similar results were found in the per protocol (PP) analyses (Table)."

Clinical • Retrospective data • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder

Ultra-Rapid Heartburn Relief and Early Mucosal Healing: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing P-CABs and PPIs (ACG 2026) - "These findings are further supported by preliminary data from the US Phase 3 TRIUMpH-EE trial (Sebela Pharmaceuticals, presented DDW 2026), which reported superior Week 2 and Week 8 healing for tegoprazan versus lansoprazole across all LA grades; full peer-reviewed results are pending. Limitations include k=5 RCTs, predominance of Asian populations for vonoprazan data, moderate Day 1 heterogeneity likely reflecting P-CAB agent and population differences, and conference-presentation status of corroborating US data. Larger confirmatory trials and US-specific subgroup analyses will be essential before guideline modification."

Retrospective data • Review • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • CYP2C19

A Quantitative Symptom-Therapy Efficacy Matching Matrix for Precision Treatment Selection in Functional Dyspepsia (ACG 2026) - "Quantitative efficacy data were extracted from five RCTs that report on five different drugs - acotiamide, itopride, buspirone, lansoprazole, and nortriptyline . Matrix-guided therapy selection demonstrated superior match scores across all profiles: pure PDS (itopride 0.317, acotiamide 0.231), pure EPS (itopride 0.307, tricyclic antidepressants 0.218, proton pump inhibitors 0.212), and nausea-dominant (itopride 0.403, tricyclic antidepressants 0.264). K-means clustering confirmed Rome IV subtype separation (k=3, silhouette score 0.771). Monte Carlo validation showed model-guided responder rates exceeded empiric care by 21â28% across profiles, with simulation error < 4% versus published RCT benchmarks."

Clinical • Dyspepsia • Musculoskeletal Pain

Beyond the Esophagus: Duodenal Strictures in Eosinophilic Esophagitis (ACG 2026) - "Case Description/ Case 1 : A 64-year-old female with EoE (E1R1E1F1S0 on initial EGD) was started on budesonide...Case 2 : A 58-year-old male with GERD and prior Schatzki ring presented with persistent dysphagia on lansoprazole...He was diagnosed with EoE, started on high-dose omeprazole, and CT enterography was planned to evaluate for strictures...Figure: Figure 2. Endoscopic image of a 9 mm duodenal stricture between the first and second portions of the duodenum in a 58-year-old male with newly diagnosed EoE, subsequently dilated to 13.5 mm."

Eosinophilia • Eosinophilic Esophagitis • Fibrosis • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Rabeprazole exhibits broad-spectrum fusion inhibition against Nipah pseudovirus and authentic HCoV-OC43 and RSV. (PubMed, Bioorg Chem) - "Systematic structure-activity relationship (SAR) profiling among clinically approved PPIs revealed that Ilaprazole and Lansoprazole exhibited stronger anti-NiV potency than Rabeprazole, while Rabeprazole sulfide showed enhanced antiviral activity relative to the parent compound. Rabeprazole also inhibited live RSV and HCoV-229E infection in a dose-dependent manner. Collectively, these findings establish the HR1 groove as a druggable pan-viral target and validate benzimidazole-based PPIs as a versatile scaffold for developing orally available, broad-spectrum antivirals against phylogenetically distinct enveloped viruses that rely on class I fusion machinery."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Lansoprazole-Induced Myoclonus. (PubMed, Tremor Other Hyperkinet Mov (N Y)) - "We present a middle-aged man who developed bilateral asterixis within few hours of the first dose of lansoprazole. Interestingly, the jerks disappeared rapidly after discontinuation of lansoprazole."

Journal • Movement Disorders

Tegoprazan Versus Lansoprazole for Endoscopic Ulcer Healing in Bleeding Peptic Ulcers (clinicaltrials.gov) - P2 | N=162 | Recruiting | Sponsor: Indonesia University | Not yet recruiting ➔ Recruiting

Enrollment open • Gastroenterology • Peptic Ulcer

A Case Report of Hematemesis in a 4-Week-Old Neonate: Clinical Reasoning and Outcome After Empiric Acid Suppression. (PubMed, Case Rep Pediatr) - "The patient was managed initially with intravenous acid suppression and supportive care, and then transitioned to oral lansoprazole...At two-week follow-up, he remained asymptomatic with normal feeding and no further bleeding episodes. This case underscores the importance of systematic evaluation in neonatal hematemesis and suggests that empiric proton pump inhibitor therapy may be a reasonable option in select stable patients with suspected mucosal injury."

Journal • Gastroenterology • Hematological Disorders

A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) (clinicaltrials.gov) - P3 | N=500 | Active, not recruiting | Sponsor: Cinclus Pharma Holding AB | Recruiting ➔ Active, not recruiting

Enrollment closed • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder

The Great Mimicker, a Rare Pleural Presentation. (PubMed, CHEST Pulm) - "Her medical history was remarkable for hypertension and a prophylactic hysterectomy 10 years previously due to a family history of ovarian cancer. Her medications included olmesartan, lansoprazole, and calcium supplements."

Journal • Cardiovascular • Gynecology • Hypertension • Oncology • Ovarian Cancer • Pulmonary Disease • Solid Tumor

Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 as Maintenance Therapy in Subjects With Healed Erosive Esophagitis (clinicaltrials.gov) - P3 | N=384 | Not yet recruiting | Sponsor: Onconic Therapeutics Inc.

Head-to-Head • New P3 trial • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder

Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer (clinicaltrials.gov) - P3 | N=384 | Not yet recruiting | Sponsor: Daewoong Pharmaceutical Co. LTD.

New P3 trial • Peptic Ulcer

Proton pump inhibitors use and the risk of osteoporosis and fractures: A two-sample Mendelian randomization study. (PubMed, Medicine (Baltimore)) - "We selected 4 representative PPIs, including omeprazole, esomeprazole, lansoprazole, and rabeprazole, for our study. Sensitivity analyses further reinforced the robustness and reliability of these findings. This MR analysis found no compelling evidence to support a causal association between PPI use and the risk of osteoporosis or fractures."

Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

A Study on the Efficacy and Safety of Finerenone on Cardiac and Renal Function in Patients with Coronary Artery Disease and Diabetes (ChiCTR) - P4 | N=120 | Not yet recruiting | Sponsor: Pharmacy Department of Su Bei People's Hospital, Jiangsu Province; Jiangsu Provincial North Jiangsu People's Hospital

New P4 trial • Cardiovascular • Coronary Artery Disease • Diabetes • Heart Failure • Metabolic Disorders

Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential Therapy (clinicaltrials.gov) - P4 | N=628 | Completed | Sponsor: Fu Jen Catholic University Hospital | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease